XWXiqiang Wang

Xiqiang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiqiang Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Gongchang Guan

    Department of Cardiology, Shaanxi Provincial People’s Hospital, Xi’an, China

    1 shared publication
  • Junkui Wang

    Department of Cardiovascular medicine, Shaanxi Provincial People's Hospital

    1 shared publication
  • Ling Zhu

    Department of Cardiology, Shaanxi Provincial People’s Hospital, Xi’an, China

    1 shared publication
  • Qianwei Cui

    Department of Cardiology, Shaanxi Provincial People’s Hospital, Xi’an, China

    1 shared publication
  • Rutai Hui

    Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • Xu Zhu

    State Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Epigenetic modification of CD4+ T cells into Tregs by 5-azacytidine as cellular therapeutic for atherosclerosis treatment

    by Ling Zhu, Zhongwei Liu, Qianwei Cui, Gongchang Guan, Rutai Hui, Xiqiang Wang, Junkui Wang, Yong Zhang, Xu Zhu

    Recent research has explored the potential of the demethylating drug 5-azacytidine (Aza) as therapy for a range of diseases. However, the therapeutic efficacy of Aza for patients of atherosclerosis remains unclear. This study investigates the therapeutic application of Aza to atherosclerosis in order to elucidate the underlying mechanisms. We generated induced Tregs (iTregs) from CD4+ T cells by using Aza in vitro, and this was followed by the intravenous infusion of iTregs for the treatment of atherosclerosis. The adoptive transfer of Aza-iTreg significantly increased peripheral blood Treg cells, suppressed inflammation, and attenuated atherosclerosis in ApoE−/− mice. Furthermore, we observed a notable demethylation of the Forkhead box P3 (Foxp3)-regulatory T cell-specific demethylated region (TSDR) and an upregulation of Foxp3 expression in the CD4+ T cells in the spleen of the ApoE−/− mice following the transfer of Aza- iTregs. We also demonstrated that Aza converted naive CD4+ T cells into Tregs by DNA methyltransferase 1 (Dnmt1)-mediated Foxp3-TSDR demethylation and the upregulation of Foxp3 expression. Conversely, the overexpression of Dnmt1 in the CD4+ T cells attenuated the Aza-induced Foxp3-TSDR demethylation and upregulation of Foxp3 expression. Our results reveal that Aza converts naive CD4+ T cells into functional Tregs by inhibiting Dnmt1, and the transfer of Aza-iTregs suppresses atherosclerosis in mice.